Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:10 PM
Ignite Modification Date: 2025-12-25 @ 2:47 PM
NCT ID: NCT02049450
Description: None
Frequency Threshold: 5
Time Frame: Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
Study: NCT02049450
Study Brief: Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
INC424 (Ruxolitinib) - Study Treatment Regularly transfused adult patients with thalassemia and spleen enlargement None None 6 30 23 30 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Anaemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (18.1) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Drug-induced liver injury SYSTEMATIC_ASSESSMENT Hepatobiliary disorders MedDRA (18.1) View
Pneumonia SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Pneumonia viral SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Anaemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (18.1) View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Constipation SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Nasopharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Pharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Alanine aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (18.1) View
Weight increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (18.1) View
Increased appetite SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (18.1) View
Pain in extremity SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (18.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (18.1) View
Pleuritic pain SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (18.1) View
Abdominal pain upper SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Gastroenteritis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Aspartate aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (18.1) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (18.1) View
Nasal congestion SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (18.1) View